Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Business, Policy & Funding › Regulatory News & FDA Approvals › CStone's NDA for Ayvakit in Molecularly Defined Stomach Cancer Accepted by Chinese Regulators

CStone's NDA for Ayvakit in Molecularly Defined Stomach Cancer Accepted by Chinese Regulators

Apr 23, 2020
|
staff reporter

NEW YORK – CStone Pharmaceuticals said on Thursday that its new drug application of avapritinib (Ayvakit) for PDGFRA exon 18-mutated metastatic or unresectable gastrointestinal stromal tumors was accepted by China's National Medical Products Administration.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Regulatory News & FDA Approvals

  1. Blueprint Medicines to Pursue Ayvakit Approval in Cancer-Causing Mast Cell Disorder

  2. Blueprint Medicine's Ayvakyt Garners Conditional European Commission Authorization in GIST

  3. EMA Committee Recommends Narrower Lynparza Indication for Metastatic Prostate Cancer Than FDA

  4. Agios's Tibsovo Trial Fails to Meet Overall Survival Endpoint in IDH1-Mutated Bile Duct Cancer

  5. EMA Committee Recommends Approval of Lynparza, Avastin in Platinum-Sensitive Ovarian Cancer

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.